Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The circulating transcriptome as a source of cancer liquid biopsy biomarkers.

Sole C, Arnaiz E, Manterola L, Otaegui D, Lawrie CH.

Semin Cancer Biol. 2019 Jan 23. pii: S1044-579X(18)30100-7. doi: 10.1016/j.semcancer.2019.01.003. [Epub ahead of print] Review.

PMID:
30684535
2.

The Circulating Transcriptome as a Source of Biomarkers for Melanoma.

Solé C, Tramonti D, Schramm M, Goicoechea I, Armesto M, Hernandez LI, Manterola L, Fernandez-Mercado M, Mujika K, Tuneu A, Jaka A, Tellaetxe M, Friedländer MR, Estivill X, Piazza P, Ortiz-Romero PL, Middleton MR, Lawrie CH.

Cancers (Basel). 2019 Jan 10;11(1). pii: E70. doi: 10.3390/cancers11010070.

3.

CircRNAs and cancer: Biomarkers and master regulators.

Arnaiz E, Sole C, Manterola L, Iparraguirre L, Otaegui D, Lawrie CH.

Semin Cancer Biol. 2018 Dec 11. pii: S1044-579X(18)30099-3. doi: 10.1016/j.semcancer.2018.12.002. [Epub ahead of print] Review.

PMID:
30550956
4.

Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases.

Goicoechea I, Rezola R, Arestin M, M Caffarel M, Cortazar AR, Manterola L, Fernandez-Mercado M, Armesto M, Sole C, Larrea E, M Araujo A, Ancizar N, Plazaola A, Urruticoechea A, Carracedo A, Ruiz I, Alvarez Lopez I, H Lawrie C.

Version 2. F1000Res. 2017 Aug 30 [revised 2018 Jan 1];6:1606. doi: 10.12688/f1000research.12393.2. eCollection 2017.

5.

Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma.

Manterola L, Aguirre P, Larrea E, Arestín M, Gaafar A, Elorriaga K, Goicoechea I, Armesto M, Fernández-Mercado M, Zabalza I, López-Duque JC, Larruskain E, Sistiaga JA, Landa M, Zabala A, Santaolalla F, Municio JA, Ispizua Á, García-Pedrero JM, Rodrigo JP, Lawrie CH.

Sci Rep. 2018 Apr 26;8(1):6613. doi: 10.1038/s41598-018-24780-7.

6.

Dysregulation of Mir-196b in Head and Neck Cancers Leads to Pleiotropic Effects in the Tumor Cells and Surrounding Stromal Fibroblasts.

Álvarez-Teijeiro S, Menéndez ST, Villaronga MÁ, Rodrigo JP, Manterola L, de Villalaín L, de Vicente JC, Alonso-Durán L, Fernández MP, Lawrie CH, García-Pedrero JM.

Sci Rep. 2017 Dec 19;7(1):17785. doi: 10.1038/s41598-017-18138-8.

7.

Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms.

Lawrie CH, Armesto M, Fernandez-Mercado M, Arestín M, Manterola L, Goicoechea I, Larrea E, Caffarel MM, Araujo AM, Sole C, Sperga M, Alvarado-Cabrero I, Michal M, Hes O, López JI.

J Mol Diagn. 2018 Jan;20(1):34-45. doi: 10.1016/j.jmoldx.2017.09.002. Epub 2017 Oct 19.

PMID:
29056573
8.

Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.

Errarte P, Beitia M, Perez I, Manterola L, Lawrie CH, Solano-Iturri JD, Calvete-Candenas J, Unda M, López JI, Larrinaga G.

PLoS One. 2017 Aug 15;12(8):e0181711. doi: 10.1371/journal.pone.0181711. eCollection 2017.

9.

Aberrant expression of MicroRNAs in B-cell lymphomas.

Sole C, Larrea E, Manterola L, Goicoechea I, Armesto M, Arestin M, Caffarel M, Araujo A, Fernandez M, Araiz M, Lawrie C.

Microrna. 2016 Aug 25. [Epub ahead of print]

PMID:
27568793
10.

New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, Caffarel MM, Araujo AM, Araiz M, Fernandez-Mercado M, Lawrie CH.

Int J Mol Sci. 2016 Apr 27;17(5). pii: E627. doi: 10.3390/ijms17050627. Review.

11.

MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential.

Fernandez-Mercado M, Manterola L, Lawrie CH.

Curr Genomics. 2015 Oct;16(5):349-58. doi: 10.2174/1389202916666150707160147.

12.

mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.

Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L, Barrena C, Villanua J, Ruiz I, Pollard S, Lovell-Badge R, Sampron N, Garcia I, Matheu A.

Expert Opin Ther Targets. 2016;20(4):393-405. doi: 10.1517/14728222.2016.1151002.

13.

The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids.

Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, Otaegui D, Lawrie CH.

J Cell Mol Med. 2015 Oct;19(10):2307-23. doi: 10.1111/jcmm.12625. Epub 2015 Jun 27. Review.

14.

A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.

Manterola L, Guruceaga E, Gállego Pérez-Larraya J, González-Huarriz M, Jauregui P, Tejada S, Diez-Valle R, Segura V, Samprón N, Barrena C, Ruiz I, Agirre A, Ayuso A, Rodríguez J, González A, Xipell E, Matheu A, López de Munain A, Tuñón T, Zazpe I, García-Foncillas J, Paris S, Delattre JY, Alonso MM.

Neuro Oncol. 2014 Apr;16(4):520-7. doi: 10.1093/neuonc/not218. Epub 2014 Jan 16.

15.

Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes.

Lawrie CH, Larrea E, Larrinaga G, Goicoechea I, Arestin M, Fernandez-Mercado M, Hes O, Cáceres F, Manterola L, López JI.

J Pathol. 2014 Jan;232(1):32-42. doi: 10.1002/path.4296.

PMID:
24155122
16.

1-42 β-amyloid peptide requires PDK1/nPKC/Rac 1 pathway to induce neuronal death.

Manterola L, Hernando-Rodríguez M, Ruiz A, Apraiz A, Arrizabalaga O, Vellón L, Alberdi E, Cavaliere F, Lacerda HM, Jimenez S, Parada LA, Matute C, Zugaza JL.

Transl Psychiatry. 2013 Jan 22;3:e219. doi: 10.1038/tp.2012.147.

17.

Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?

Ballabio E, Armesto M, Breeze CE, Manterola L, Arestin M, Tramonti D, Hatton CS, Lawrie CH.

Blood Cancer J. 2012 Aug 24;2:e83. doi: 10.1038/bcj.2012.31. No abstract available.

18.

Oncogenicity of the developmental transcription factor Sox9.

Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, Canamero M, Bujanda L, Schedl A, Cheah KS, Skotheim RI, Lothe RA, López de Munain A, Briscoe J, Serrano M, Lovell-Badge R.

Cancer Res. 2012 Mar 1;72(5):1301-15. doi: 10.1158/0008-5472.CAN-11-3660. Epub 2012 Jan 13.

19.

Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas.

Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, Lopez de Munain A, Sampron N, Aramburu A, Tejada-Solís S, Vicente C, Odero MD, Bandrés E, García-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C.

PLoS One. 2011;6(11):e26740. doi: 10.1371/journal.pone.0026740. Epub 2011 Nov 1.

20.

Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10.

Díaz-Valdés N, Manterola L, Belsúe V, Riezu-Boj JI, Larrea E, Echeverria I, Llópiz D, López-Sagaseta J, Lerat H, Pawlotsky JM, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Hepatology. 2011 Jan;53(1):23-31. doi: 10.1002/hep.23980. Epub 2010 Dec 13.

21.

BvrR/BvrS-controlled outer membrane proteins Omp3a and Omp3b are not essential for Brucella abortus virulence.

Manterola L, Guzmán-Verri C, Chaves-Olarte E, Barquero-Calvo E, de Miguel MJ, Moriyón I, Grilló MJ, López-Goñi I, Moreno E.

Infect Immun. 2007 Oct;75(10):4867-74. Epub 2007 Jul 30.

22.

Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.

Grilló MJ, Manterola L, de Miguel MJ, Muñoz PM, Blasco JM, Moriyón I, López-Goñi I.

Vaccine. 2006 Apr 5;24(15):2910-6. Epub 2006 Jan 6.

PMID:
16439039
23.

The lipopolysaccharide of Brucella abortus BvrS/BvrR mutants contains lipid A modifications and has higher affinity for bactericidal cationic peptides.

Manterola L, Moriyón I, Moreno E, Sola-Landa A, Weiss DS, Koch MH, Howe J, Brandenburg K, López-Goñi I.

J Bacteriol. 2005 Aug;187(16):5631-9.

24.

Evaluation of a PCR test for the diagnosis of Brucella ovis infection in semen samples from rams.

Manterola L, Tejero-Garcés A, Ficapal A, Shopayeva G, Blasco JM, Marin CM, López-Goñi I.

Vet Microbiol. 2003 Mar 20;92(1-2):65-72.

PMID:
12488071
25.

Regulation of Brucella virulence by the two-component system BvrR/BvrS.

López-Goñi I, Guzmán-Verri C, Manterola L, Sola-Landa A, Moriyón I, Moreno E.

Vet Microbiol. 2002 Dec 20;90(1-4):329-39. Review.

PMID:
12414153
26.

The two-component system BvrR/BvrS essential for Brucella abortus virulence regulates the expression of outer membrane proteins with counterparts in members of the Rhizobiaceae.

Guzman-Verri C, Manterola L, Sola-Landa A, Parra A, Cloeckaert A, Garin J, Gorvel JP, Moriyon I, Moreno E, Lopez-Goni I.

Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12375-80. Epub 2002 Sep 6.

Supplemental Content

Loading ...
Support Center